N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.

Abstract

N-Acetylaspartylglutamate (NAAG) is the third most prevalent neurotransmitter in the mammalian nervous system, yet its therapeutic potential is only now being fully recognized. Drugs that inhibit the inactivation of NAAG by glutamate carboxypeptidase II (GCPII) increase its extracellular concentration and its activation of its receptor, mGluR3. These drugs warrant attention, as they are effective in animal models of several clinical disorders including stroke, traumatic brain injury and schizophrenia. In inflammatory and neuropathic pain studies, GCPII inhibitors moderated both the primary and secondary pain responses when given systemically, locally or in brain regions associated with the pain perception pathway. The finding that GCPII inhibition also moderated the motor and cognitive effects of ethanol intoxication led to the discovery of their procognitive efficacy in long-term memory tests in control mice and in short-term memory in a mouse model of Alzheimer's disease. NAAG and GCPII inhibitors respectively reduce cocaine self-administration and the rewarding effects of a synthetic stimulant. Most recently, GCPII inhibition also has been reported to be efficacious in a model of inflammatory bowel disease. GCPII was first discovered as a protein expressed by and released from metastatic prostate cells where it is known as prostate specific membrane antigen (PSMA). GCPII inhibitors with high affinity for this protein have been developed as prostate imaging and radiochemical therapies for prostate cancer. Taken together, these data militate in favor of the development and application of GCPII inhibitors in more advanced preclinical research as a prelude to clinical trials.

• Authors: Joseph H Neale, Tatsuo Yamamoto
• Journal: Progress in neurobiology (Prog Neurobiol) Vol. 184 Pg. 101722 (01 2020) ISSN: 1873-5118 [Electronic] England
• PMID: 31730793 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Dipeptides
• Neurotransmitter Agents
• Nootropic Agents
• Protease Inhibitors
• isospaglumic acid
• Glutamate Carboxypeptidase II

Topics

• Animals
• Dipeptides (antagonists & inhibitors)
• Glutamate Carboxypeptidase II (antagonists & inhibitors)
• Humans
• Inflammatory Bowel Diseases (drug therapy)
• Mental Disorders (drug therapy)
• Neoplasms (drug therapy)
• Nervous System Diseases (drug therapy)
• Neurotransmitter Agents (pharmacology)
• Nootropic Agents (pharmacology)
• Protease Inhibitors (pharmacology)